Institute of Medical Virology, Helmut-Ruska-Haus, Charité University Medicine, 10117 Berlin, Germany.
Med Microbiol Immunol. 2012 Aug;201(3):277-86. doi: 10.1007/s00430-012-0229-2.
Primary infection and reactivation of human cytomegalovirus (CMV) remain a major problem in immunocompromised patients, frequently resulting in a life threatening CMV disease. Intravenous polyvalent (hyper)-immunoglobulins (IVIG) can be administered for therapy and prophylaxis of CMV infections. However, only limited data about the efficacy and mechanism of action of IVIG products against viral infections in vitro are available so far. In this study, the effect of IVIG on CMV infection in vitro was investigated using isolates from CMV-infected patients as well as the laboratory strains AD169 and TB40. A qualitative and quantitative comparison of five different commercially available IVIG products in different human cell lines was performed concerning their ability (1) to neutralize cell-free virus, (2) to inhibit cell-to-cell spread and cell-associated transmission and (3) to influence CMV mRNA levels. All IVIG tested exhibited a high neutralization activity in epithelial and endothelial cell cultures (50% inhibition dose <0.1 mg/ml). However, qualitative differences between the products could be demonstrated in neutralization tests using human embryonal lung fibroblasts (HELF). The IVIG products also significantly differed in their ability to inhibit cell-to-cell spread within an CMV-infected HELF monolayer displaying inhibition rates that varied between 61 and 100%. No correlation between the ability to neutralize cell-free virus and to inhibit cell-to-cell spread could be observed. The incubation with IVIG influenced the amount of CMV immediate early and late mRNA, as indicated by a significant reduction in CMV mRNA in infected epithelial cells after incubation with IVIG in a dose-dependent manner. This study suggests different antiviral functions of polyvalent IVIG and confirms their potential to inhibit a CMV infection in vitro, with profound differences between the hereby used IVIG products.
人巨细胞病毒(CMV)的原发感染和再激活仍然是免疫功能低下患者的一个主要问题,经常导致危及生命的 CMV 疾病。静脉注射多价(超)免疫球蛋白(IVIG)可用于 CMV 感染的治疗和预防。然而,迄今为止,关于 IVIG 产品在体外针对病毒感染的疗效和作用机制的有限数据。在这项研究中,使用来自 CMV 感染患者的分离物以及实验室株 AD169 和 TB40,研究了 IVIG 对体外 CMV 感染的影响。在不同的人细胞系中,对五种不同市售 IVIG 产品进行了定性和定量比较,评估它们(1)中和无细胞病毒的能力,(2)抑制细胞间传播和细胞相关传播的能力,以及(3)影响 CMV mRNA 水平的能力。所有测试的 IVIG 在上皮细胞和内皮细胞培养物中均表现出高中和活性(50%抑制剂量<0.1 mg/ml)。然而,在使用人胚肺成纤维细胞(HELF)的中和试验中,可以证明产品之间存在定性差异。IVIG 产品在抑制 CMV 感染 HELF 单层细胞间传播的能力方面也存在显著差异,抑制率在 61%至 100%之间。未能观察到中和无细胞病毒的能力与抑制细胞间传播的能力之间存在相关性。IVIG 的孵育影响 CMV 即刻早期和晚期 mRNA 的数量,如在用 IVIG 孵育后,感染上皮细胞中的 CMV mRNA 显著减少,呈剂量依赖性。本研究表明多价 IVIG 具有不同的抗病毒功能,并证实其具有抑制体外 CMV 感染的潜力,所使用的 IVIG 产品之间存在显著差异。